BiotechTube
LungLife AI

LungLife AI

Thousand Oaks, United States· Est.
lunglifeai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.5M

Overview

LungLife AI is a developer of clinical diagnostic solutions targeting the early detection of lung cancer, the world's deadliest cancer. Its flagship product, the LungLB® test, uses a simple blood draw and AI analysis to help clinicians manage patients with indeterminate lung nodules, aiming to improve outcomes through earlier intervention. The company operates a CLIA lab and appears to be in the commercial or late-stage validation phase for its diagnostic. Leadership combines deep expertise in translational lung cancer research, liquid biopsy technology, and financial management.

Oncology

Technology Platform

Blood-based liquid biopsy (LungLB® test) utilizing circulating tumor cell (CTC) enrichment and analysis enhanced by artificial intelligence/machine learning algorithms.

Funding History

2
Total raised:$18.5M
Series A$15M
Seed$3.5M

Opportunities

The massive clinical need to manage millions of indeterminate lung nodules detected annually presents a large addressable market.
A successful blood-based test can reduce invasive procedures, lower healthcare costs, and accelerate treatment, driving payer interest.
Leadership's specific expertise in lung cancer liquid biopsy provides a focused competitive advantage.

Risk Factors

The company faces significant competition from larger liquid biopsy firms and must prove clinical utility to change medical practice.
Securing insurance reimbursement is a major hurdle for commercial success.
As a public, single-product company, it is vulnerable to clinical data setbacks, slower adoption, and financial market volatility.

Competitive Landscape

LungLife AI competes in the crowded liquid biopsy space against well-funded giants like Guardant Health and Grail (Illumina), which have broader early detection ambitions. It also competes with other diagnostic companies focusing on lung nodules via imaging AI or molecular tests. Its differentiation is a specialized focus on the post-nodule-discovery clinical decision point, rather than primary screening.

More companies in AI / Machine Learning →More companies in United States →